Overview HSK7653 in Chinese Patients With Impaired Glucose Tolerance Status: Recruiting Trial end date: 2022-06-28 Target enrollment: Participant gender: Summary This study is being done to evaluate the efficacy, safety of HSK7653 in chinese participants with impaired glucose tolerance. Phase: Phase 2 Details Lead Sponsor: Haisco Pharmaceutical Group Co., Ltd.